Charities Pick Up Slack As Pharmaceutical Funders

Disease charities are increasingly breaking out of their traditional role as advocates and funders of academic research and venturing into industry partnerships to fund early stage drug research programs. Valued at more than $100 million, the funding is critical in bridging the gap between NIH investment and venture capitalists wary of investing in risky drugs, particularly given the present economic and health care uncertainties.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail